Cervical cancer is the most common gynecologic malignancy. The migratory zone of the uterine cervix is a favored site for cervical cancer. It is currently believed that during the development of the migratory zone, excessive cervical epithelial hyperplasia combined with stimulation by foreign substances forms cervical intraepithelial neoplasia (CIN). As CIN develops, it breaks through the basement membrane to infiltrate the mesenchyme to form invasive carcinoma. Generally, it takes 10-15 years to develop from CIN to invasive carcinoma, but 25% develop into invasive carcinoma within 5 years. Pathologically, cervical cancer is divided into squamous carcinoma (about 85%) and adenocarcinoma (about 15%). The common symptoms of cervical cancer are vaginal bleeding and vaginal discharge. Early stages are often asymptomatic and the cervix may be smooth and indistinguishable from chronic cervicitis. The use of cervical cytology screening has allowed early detection and treatment of cervical cancer. Treatment options include surgery, chemotherapy and radiotherapy, and a combination of chemotherapy and surgery. Squamous cervical cancer is sensitive to chemotherapy and has good efficacy. In the past, physicians mostly used intravenous chemotherapy, which resulted in a large patient response and significant hair loss, while arterial chemoembolization significantly reduced post-chemotherapy pain and greatly improved hair loss. Moreover, embolization of tumor vessels after chemotherapy significantly shrinks the tumor and even achieves histological cure in some patients. For stage Ia~IIb cervical cancer, arterial chemoembolization followed by surgical resection has significantly better survival than that of patients treated with surgery alone. For advanced stage patients, arterial chemoembolization can not only treat the primary tumor, but also treat the pelvic and vaginal metastases (direct spread is the main metastatic route of cervical cancer), which is a less painful and more effective treatment.